{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:16:08Z","timestamp":1782832568104,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1053\/j.seminoncol.2007.11.005","type":"journal-article","created":{"date-parts":[[2008,1,7]],"date-time":"2008-01-07T07:19:03Z","timestamp":1199690343000},"page":"S35-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S5","title":["Forodesine Treatment and Post-Transplant Graft-Versus-Host Disease in Two Patients With Acute Leukemia: Facilitation of Graft-Versus-Leukemia Effect?"],"prefix":"10.1053","volume":"34","author":[{"given":"Lia","family":"Gore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Quinones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.005_bib1","first-page":"524a","article-title":"Forodesine IV (BCX-1777) is clinically active in relapsed\/refractory T-cell leukemia: Results of a phase II study (interim report)","volume":"108","author":"Furman","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.005_bib2","first-page":"750a","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I\/II studies in patients with B-cell acute lymphoblastic leukemia","volume":"104","author":"Furman","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.005_bib3","first-page":"259a","article-title":"Forodesine (Fodosine\u2122), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase II study)","volume":"106","author":"Furman","year":"2005","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.005_bib4","first-page":"196a","article-title":"Outcome for adolescent and young adults 16-21 years of age (AYA) with ALL treated on the Children\u2019s Cancer Group (CCG) 1961 study","volume":"104","author":"Nachman","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib5","first-page":"243","article-title":"Purine nucleoside phosphorylase inhibitors in T-cell malignancies","volume":"7","author":"Bantia","year":"2004","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/00912700022008991","article-title":"Pharmacokinetics and pharmacodynamics of Peldesine (BCX-34), on activation and proliferation of normal human lymphoid cells","volume":"40","author":"Viegas","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2014a novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib8","series-title":"Hematopoietic Cell Transplantation","first-page":"515","article-title":"Graft-versus-host disease","author":"Sullivan","year":"1999"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.005_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10245330512331389953","article-title":"Current issues in allogeneic stem cell transplantation","volume":"10","author":"Socie","year":"2005","journal-title":"Hematology"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.TP.0000106475.38978.11","article-title":"Suppression of graft-versus-host disease by naturally occurring regulatory T cells","volume":"77","author":"Zeng","year":"2004","journal-title":"Transplantation"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1365-2567.2003.01687.x","article-title":"CD8+ immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12\/interleukin-18 and induce T helper 1 autoantibody","volume":"109","author":"Noble","year":"2003","journal-title":"Immunology"},{"key":"10.1053\/j.seminoncol.2007.11.005_bib13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1567-5769(02)00034-6","article-title":"Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: The role of the dGTP in antiproliferative action of BCX-1777","volume":"2","author":"Bantia","year":"2002","journal-title":"Int Immunopharmacol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:57:53Z","timestamp":1758794273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775407002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":13,"alternative-id":["S0093775407002242"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.11.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Forodesine Treatment and Post-Transplant Graft-Versus-Host Disease in Two Patients With Acute Leukemia: Facilitation of Graft-Versus-Leukemia Effect?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}